藥學科技二 - scifinder& innovation 系級：藥三A 學號：B303098012 姓名：林千玉 查詢項目：diclofenac sodium Scifinder 查詢之結果：
Effect of Phenobarbital on metabolism and toxicity of diclofenac sodium in vitro
Abstract:To investigate the effects of phenobarbital (PB) on metab. and toxicity of diclofenac sodium (DF-Na) in vitro, rathepatocytes were isolated and cultured with sandwich method. The enzyme leakage level, cytochrome P 450 3A (CYP3A) activity, and metabolite content of DF-Na in cell culture medium were measured after hepatocytes or PB pre-treatedhepatocytes were incubated with DF-Na in vitro. Basic hepatic CYP 3A activity gradually decreased with culture time.The decline of CYP 3A was partially reversed by usingcytochrome P 450 inducer such as PB. The activities of lacticdehydrogenase (LDH), alanine aminotransferase (ALT) and aspartate
aminotransferase (AST), and the contents ofmetabolite 4'-hydroxydiclofenac (4'-OH-DF) and 5-hydroxydiclofenac (5-OH-DF) in supernatants were found to increasewith the DF-Na exposure concns. But there were no significant difference between exposed group and control group.However, if the hepatocytes were first
pre-treated with PB and then exposed to DF-Na, the concns. of DF-Na
metabolitesand the activity of LDH in the supernatants were significantly higher than those of control group. The hepatotoxicity andmetab.of DF-Na in rat hepatocytes should be increased when CYP 3A activity increased.
Formulation and evaluation of diclofenac sodium ophthalmic inserts Abstract:Diclofenac sodium circular ophthalmic inserts were prepd. by solvent casting method, using gelatin as a polymer at 2different concns. (18% w/v and 20% w/v) and glycerin as a plasticizer in 2 different concns. (70% vol./vol. and 50%vol./vol.) on dry wt. of gelatin. An in vitro method was designed and utilized for the study. Inserts release the drug as afunction of square root of time. In vivo release of the inserts was detd. in albino rabbits. In vitro methods simulated invivo conditions, which was confirmed by strong +ve correlation (+0.975) between the 2 results indicating that insertscould control drug release and might improve ocular bioavailability and reduce toxicity of Diclofenac sodium.
Clinical study on effect of total Panaxnotoginsengsaponins on immune related inner environment imbalance in rheumatoid arthritis patients
Abstract:Objective: To study the therapeutic effect and possible mechanism of total Panaxnotoginsengsaponins (PNS) fortreatment of rheumatoid arthritis (RA), and to observe its safety and influence on RA immune related inner environment.Methods: Eighty-four patients were randomly assigned to two groups. All were treated with the routine therapy withdiclofenac sodium, leflunomide and prednisone, but for the 43 patients in the treatment group PNS was given addnl. Thetherapeutic course was 28 days for both groups. Clin.efficacy and change of indexes including platelet counts, Igs (IgG,IgA, IgM), complement (C)3, rheumatoid factor (RF), C-reactive protein (CRP), ceruloplasmin (CER), haptoglobin (HPT),and a1-acid glycoprotein (AAG) were obsd. Results: Significant improvement of clin. symptoms, including the jointswelling index, joint tenderness index, joint pain index, time of morning stiffness and VAS revealed in both groups aftertreatment, and the effect in the treatment group was better (P < 0.05 or P < 0.01). PLT, CER, AAG, HPT, CRP, IgG, IgA,IgM, C3 and RF were lowered in both groups (P < 0.01), but the lowering in PLT, CER, AAG and CRP in the treatment group was more significant than that in the control group resp. (P < 0.05 or P < 0.01). Conclusion: PNS can significantlyimprove the condition of patients, enhance the therapeutic effect in treating RA, through regulating the disorderedimmunity and improving the effect of anti-inflammatory and analgesia.
Therapeutic efficacy of diclofenac sodium suppositories perrectum in renal colic caused by calculus
Abstract:This paper studies the therapeutic efficacy of diclofenac sodium suppositories in renal colic caused by calculus. 236Cases of acute renal colic in
emergency department of our hospital are analyzed. All cases were divided into controlgroup (conventional therapy) and diclofenac sodium group. The efficacy of two groups was studied after being treatedtwo hours, eight hours, 24 h, resp. Cases of two groups which were treated by pethidine were compared with at thesame time. There was statistics difference in efficacy when diclofenac sodium groups was compared with control groupafter being treated two hours, eight hours, resp. (P<0.05). There was no statistics difference in efficacy of two groupsafter being treated 24 h (P>0.05). There was statistics difference in two groups in cases which were treated by pethidine.Diclofenac sodium suppositories can be used in treatment of acute renal colic and the efficacy is better than that ofconventional therapy and the using of pethidine can be limited also.
Scifinder 之心得：
透過Scifinder 使用的學習，可以讓找資料的效率提高，相較於以前透過一般
網頁的搜尋，往往會無法確定資料的正確性，現在使用scifinder的可信度高，
搜尋的功能也很多樣化，圖像和文字都可以，是準備報告、查詢資料的好工 具。這次我利用scifinder 查詢 diclofenac sodium，在 NSAID 中使用廣泛的藥
物，從它的結構、合成方法、治療用途、副作用和毒性等，在scifinder 輸入 關鍵字後，都可以找到相關資料，大部分的摘要，都以實驗作為說明，對照 組與實驗組的比較下，可以明確得知藥物在體外和治療上的效益。同時也要 謝謝老師替我們找了專業的講者，教導我們如何使用，也讓我們實際操作練 習，除了對於未來資料查詢有很大的幫助，也讓我們平時就能學習到不限於 課堂內的知識。 查詢時的頁面
INNOVATION 查詢之結果：
Cardiac hormones for assessing cardiovascular risk
Abstract: The present invention relates to the use of cardiac hormones, particularly
natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a cox-2-inhibiting compound, in particular an NSAID, selective cox-2 inhibitor, or steroid. More particularly, the present invention relates to the use of cardiac hormones, particularly natriuretic peptides, for diagnosing the cardiovascular risk of a patient who is a candidate for administration of a selective cox-2 inhibitor and further provides methods for diagnosing the risk of a patient to suffer from a cardiovascular complication as a consequence of administration of a cox-2 inhibiting compound.
Fluorocytidine derivatives and COX-2 inhibitors for the treatment of cancer Abstract: The present invention provides, in certain embodiments, methods for the treatment of colorectal cancer comprising administering a COX-2 inhibitor and fluorocytidine derivative to a human patient. In certain embodiments, a radiation therapy is also administered to the patient.
Combinations comprising a selective COX-2 inhibitor and a microtubule interfering agent
Abstract:Disclosed is a combination which comprises (a) a selective cyclooxygenase-2 inhibitor of the formula (I), wherein the substituents are as defined in the specification, and (b) a microtubule interfering agent, in which the active ingredients (a) and (b) are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use with the proviso that the microtubule interfering agent is not epothilone.
Use of selective COX-2 inhibitors for the treatment of urinary incontinence Abstract:The treatment of neuromuscular dysfunction of the lower urinary tract by compounds which selectively inhibit the COX-2 isozyme is described. The compounds concerned inhibit the COX-2 isozyme with a potency at least 10-fold, and preferably at least 100-fold, greater than their potency on the COX-1 isozyme.
USE OF AN AMYLOID BETA VACCINATION IN COMBINATION WITH A SELECTIVE COX-2 INHIBITOR FOR THE TREATMENT OF ALZHEIMER'S DISEASE.
treatment or prevention of Alzheimer's disease. More particularly, the invention provides a combination therapy for the treatment or prevention of Alzheimer's disease, wherein the therapy comprises administering to a subject an amyloid beta vaccine in combination with a cyclooxygenase-2 selective inhibitor.
INNOVATION 之心得： 以前也有上過關於專利的課程，但沒有學過如何利用INNOVATION 獲得與專 利相關的資訊，INNOVATION 提供了我們一個查詢專利的好平台，儘管不是 完全的版本，但是在使用方面還是有一定程度上的幫助。在練習查詢的過程 中十分有趣，因為有些產品或是介面的專利，在發明和應用上很特別，有些 則是我們生活中不可或缺或是非常平常的小事物，透過INNOVATION 這個平 台我們可以更清楚的了解它的用途。我利用INNOVATION 搜尋了 selective cox-2 inhibitor，在課堂中我們對它的認知為 NSAID 中極具開發潛力的方向， 在查詢的資訊當中，得到了一些治療上應用和機轉的資料，有些治療方法可 能是我們還未曾有的想法，但已經有相關的研究和專利，這些讓我們可以更 進一步的學習。
